awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q52643766-2C848A74-BD64-4CB0-9128-7F943458B1AE
Q52643766-2C848A74-BD64-4CB0-9128-7F943458B1AE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52643766-2C848A74-BD64-4CB0-9128-7F943458B1AE
Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?
P2860
Q52643766-2C848A74-BD64-4CB0-9128-7F943458B1AE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52643766-2C848A74-BD64-4CB0-9128-7F943458B1AE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e579a5579ac4d9432e2c458e779a572868db6008
P2860
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.